COMMUNIQUÉS West-GlobeNewswire

-
Strength Training For Women: CrazyBulk Legal Steroid Alternatives Are Changing the Muscle Building Supplements Game
14/07/2025 -
Personal Health Data Finally Simplified: Meet Validic Sparks
14/07/2025 -
Bonus Biogroup Appoints Renowned Cell Therapy Leader, Professor Edwin M. Horwitz, MD, PhD, to its Advisory Board
14/07/2025 -
I-Mab to Present at the BTIG Virtual Biotechnology Conference
14/07/2025 -
Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025
14/07/2025 -
Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET
14/07/2025 -
Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042
14/07/2025 -
Kraig Biocraft Laboratories Announces Second Production Facility, Three Advanced Spider Silk Strains, and New Diapausing System
14/07/2025 -
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma
14/07/2025 -
Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions
14/07/2025 -
Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research
14/07/2025 -
Hydreight Technologies Signs Binding Letter of Intent to Acquire 5% Equity Stake in Perfect Scripts, LLC, with Option to Increase to 40%, and Establish Strategic Partnership
14/07/2025 -
Gero Appoints Longevity Expert Dr. Brian Kennedy to Board of Directors
14/07/2025 -
Synergy CHC Corp. (NASDAQ: SNYR) Secures Retail Deals with McKesson Canada and Others as FOCUSfactor Expansion Surges Across North America
14/07/2025 -
Santé Canada étend l’approbation d’Evkeeza® (évinacumab) chez les enfants âgés d’à peine 6 mois atteints d’hypercholestérolémie familiale homozygote (HFHo)
14/07/2025 -
Health Canada Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)
14/07/2025 -
JenaValve Announces First Patient Enrolled in ARTIST Randomized Controlled Trial (RCT) Evaluating the Trilogy™ System in Aortic Regurgitation (AR)
14/07/2025 -
Recludix Pharma Announces Strengthening of Leadership Team, Including Promotion of Dr. Brian Hodous to Chief Scientific Officer
14/07/2025 -
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
14/07/2025
Pages